Bristol-Myers Squibb Co (MIL:1BMY) ROCE %: 21.95% (As of Mar. 2026)


MIL:1BMY Bristol-Myers Squibb Co MIL:1BMY
49 GF Score
Price €50.56
GF Value €48.51
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Bristol-Myers Squibb Co ROCE %?

Bristol-Myers Squibb Co MIL:1BMY +3.14% 49 ROCE % is 21.95% as of Mar. 2026. GuruFocus rates MIL:1BMY with a GF Score™ of 49/100 and a GF Value™ of €48.51 (Fairly Valued). The stock has 7 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Bristol-Myers Squibb Co's annualized ROCE % for the quarter that ended in Mar. 2026 was 21.95%.

Bristol-Myers Squibb Co  (MIL:1BMY) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Bristol-Myers Squibb Co ROCE % Related Terms

Bristol-Myers Squibb Co ROCE % Historical Data

* Premium members only.

The historical data trend for Bristol-Myers Squibb Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bristol-Myers Squibb Co ROCE % Chart

Bristol-Myers Squibb Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.49 11.40 12.81 -9.27 15.63

Bristol-Myers Squibb Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.88 12.90 20.97 11.25 21.95
MIL:1BMY
49GF Score
Bristol-Myers Squibb Co MIL:1BMY
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bristol-Myers Squibb Co ROCE % Calculation

Bristol-Myers Squibb Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=9581.026/( ( (88435.865 - 22704.17) + (76892.452 - 19998.118) )/ 2 )
=9581.026/( (65731.695+56894.334)/ 2 )
=9581.026/61313.0145
=15.63 %

Bristol-Myers Squibb Co's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=12632.46/( ( (76892.452 - 19998.118) + (74801.74 - 16571.67) )/ 2 )
=12632.46/( ( 56894.334 + 58230.07 )/ 2 )
=12632.46/57562.202
=21.95 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 21.95% mean?
Bristol-Myers Squibb Co (MIL:1BMY) has a ROCE % of 21.95% as of Mar. 2026.
Is Bristol-Myers Squibb Co's ROCE % too high?
Bristol-Myers Squibb Co's current ROCE % is 21.95%. The Drug Manufacturers industry median ROCE % is 7.00. Bristol-Myers Squibb Co's value of 21.95% is 213.8% above this industry median. Overall, Bristol-Myers Squibb Co has a GF Score™ of 49/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bristol-Myers Squibb Co's ROCE % compare to PFE and GILD?
Bristol-Myers Squibb Co's ROCE % of 21.95% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.00. Bristol-Myers Squibb Co's value of 21.95% is 213.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bristol-Myers Squibb Co's current ROCE % of 21.95% is 213.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bristol-Myers Squibb Co's current ROCE % is 21.95%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bristol-Myers Squibb Co stock overvalued right now?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co (MIL:1BMY) is currently considered Fairly Valued. The stock's GF Value™ is €48.51, compared to a current price of €50.56 — trading 4.2% above its estimated fair value. The current ROCE % is 21.95% and 213.8% above the Drug Manufacturers industry median of 7.00. Bristol-Myers Squibb Co's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Bristol-Myers Squibb Co (MIL:1BMY), the current ROCE % is 21.95% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bristol-Myers Squibb Co (MIL:1BMY) Overvalued in 2026?

Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued. The current stock price of €50.56 is trading 4.2% above its estimated GF Value™ of €48.51. GuruFocus considers Bristol-Myers Squibb Co to be Fairly Valued.

Key valuation signals for MIL:1BMY:

  • ROCE %: 21.95%
  • GF Value™: €48.51 vs. price of €50.56 (4.2% above fair value)
  • GF Score™: 49/100 with 7 warning signs
  • Industry Position: 213.8% above the Drug Manufacturers median

No single metric tells the full story. See the MIL:1BMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bristol-Myers Squibb Co Business Description

Address Route 206 and Province Line Road, Princeton, New Jersey, NJ, USA, 08543
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
49GF Score

Get the complete analysis for MIL:1BMY

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€50.56
Price
€48.51
GF Value